Oxford BioDynamics reported that losses increased in the year-end, 30 September. This resulted in shares falling 4.8% and 14.5p respectively.
Operating losses decreased to £8.6mln from £7.5mln one year ago. This was due to increased staff costs, general and administrative costs, and depreciation.
Although it received a £400,000 funding grant, its revenue fell to £200,000 from £300,000.
Oxford Biodynamics, a global biotechnology company, stated that it specializes in personalized healthcare. It develops and commercializes precision medicine tests to treat life-altering diseases.
Oxford BioDynamics participated in over 40 partnerships with major pharma companies and top institutions, including Genentech, EMD Serono, and Pfizer.
Chief executive Jon Burrows stated that “we made substantial progress in 2022 with the strategy we presented shareholders in 2020 – pivoting to a more profitable footing, and developing proprietary tests using EpiSwitch platform,”
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.